Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
Myocardial infarction (MI), commonly known as a heart attack, is a critical medical condition requiring immediate attention and long-term management. Secondary prevention focuses on preventing subsequent cardiovascular events in patients who have already experienced an MI. Key guidelines for secondary prevention of MI have been established by agencies such as the National Institute for Health and Care Excellence (NICE), the American Heart Association (AHA), and the European Heart Association (EHA). This article provides a comprehensive overview of the drugs recommended for secondary prevention of myocardial infarction, focusing on their mechanisms, indications, and clinical evidence.
A summary of guidance by NICE for people who have had an MI
| Drug Therapy for Secondary Prevention | Details |
|---|---|
| ACE Inhibitor (or ARB if intolerant) | Continue indefinitely |
| Dual Antiplatelet Therapy (aspirin + second antiplatelet) | Continue for up to 12 months, unless there is a separate indication for anticoagulation |
| Beta-blocker (or diltiazem/verapamil if contraindicated and no pulmonary congestion or reduced left ventricular ejection fraction) | Continue indefinitely if reduced left ventricular ejection fraction, otherwise consider continuing for at least 12 months |
| Statin | Recommended for adults with clinical evidence of cardiovascular disease in line with the NICE guideline on cardiovascular disease |
| Antiplatelet Therapy with an Indication for Anticoagulation | Do... |
Try our Free Plan to get the full article.
